Identification of the immunodominant CTL epitope of EGFP in C57BL/6 mice

This publication has 10 references indexed in Scilit:

• The immune response to lentiviral-delivered transgene is modulated in vivo by transgene-expressing antigen-presenting cells but not by CD4+CD25+ regulatory T cells
  Blood, 2007
• Engraftment of retroviral EGFP-transduced bone marrow in mice prevents rejection of EGFP-transgenic skin grafts
  Molecular Therapy, 2003
• Nonmyeloablative conditioning is sufficient to allow engraftment of EGFP-expressing bone marrow and subsequent acceptance of EGFP-transgenic skin grafts in mice
  Blood, 2003
• The enhanced green fluorescent protein (eGFP) is minimally immunogenic in C57BL/6 mice
  Gene Therapy, 2001
• EGFP-transduced EL-4 cells from tumors in C57BL/6 mice
  Gene Therapy, 2001
• Induction of cytotoxic T lymphocyte and antibody responses to enhanced green fluorescent protein following transplantation of transduced CD34+ hematopoietic cells
  Blood, 2001
• Immunogenicity of enhanced green fluorescent protein (EGFP) in BALB/c mice: identification of an H2-Kd-restricted CTL epitope
  Gene Therapy, 2000
• Immune response to green fluorescent protein: implications for gene therapy
  Gene Therapy, 1999
• Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains.
  The Journal of Immunology, 1994
• Selective rejection of H–2-deficient lymphoma variants suggests alternative immune defence strategy
  Nature, 1986